Abstract
There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 965-973 |
| Number of pages | 9 |
| Journal | Neuropsychiatric Disease and Treatment |
| Volume | 3 |
| Issue number | 6 |
| State | Published - Dec 1 2007 |
Fingerprint
Keywords
- Adverse effects
- Antipsychotic drugs
- Pharmacogenetics
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
Cite this
Pharmacogenetics of antipsychotic adverse effects : Case studies and a literature review for clinicians. / Foster, Adriana; Wang, Zixuan; Usman, Manzoor; Stirewalt, Edna; Buckley, Peter.
In: Neuropsychiatric Disease and Treatment, Vol. 3, No. 6, 01.12.2007, p. 965-973.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pharmacogenetics of antipsychotic adverse effects
T2 - Case studies and a literature review for clinicians
AU - Foster, Adriana
AU - Wang, Zixuan
AU - Usman, Manzoor
AU - Stirewalt, Edna
AU - Buckley, Peter
PY - 2007/12/1
Y1 - 2007/12/1
N2 - There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.
AB - There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.
KW - Adverse effects
KW - Antipsychotic drugs
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=38149131166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38149131166&partnerID=8YFLogxK
M3 - Review article
VL - 3
SP - 965
EP - 973
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
SN - 1176-6328
IS - 6
ER -